News & Updates

Treatment with deucravacitinib demonstrates its superiority to placebo across several endpoints in patients with psoriatic arthritis (PsA) at week 16, according to the phase III POETYK PsA-2 study. Clinical responses have also persisted for up to a year.

Individuals with high adherence to the Mediterranean diet (MD) appear to benefit from a reduced risk of rheumatoid arthritis (RA), suggests a study.

Treatment with tofacitinib improves the rates of Juvenile Arthritis Disease Activity Score (JADAS) in 10 joints (JADAS10)-clinically inactive disease (CID) and American College of Rheumatology (ACR)-CID in patients with juvenile idiopathic arthritis (JIA), with improvements sustained over time, a study has shown. Additionally, a few patients have achieved JADAS10 remission.